Turnstone Biologics

Turnstone Biologics, a clinical-stage biotechnology company founded in 2015, is focused on developing next-generation TIL-based therapies to treat and cure solid tumors. The company's differentiated approach centers around pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. This innovative therapy is based on the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TILs. Turnstone is actively progressing its most advanced program, TIDAL-01, which is currently undergoing evaluation in multiple Phase 1 studies for various cancer types, including colorectal cancer, breast cancer, head and neck cancer, uveal melanoma, and cutaneous melanoma. The company's focus on overcoming the limitations of first-generation bulk TIL therapy, which has shown objective responses only in limited tumor types, sets it apart in the industry. Turnstone is also advancing its preclinical pipeline programs, including TIDAL-02, the next Selected TIL program, and a program that combines TIDAL-01 with viral immunotherapy. As of July 14, 2021, Turnstone Biologics secured a significant $80.00M Series D investment, with key investors such as Versant Ventures, 60 Degree Capital, Brace Pharma Capital, JM Family Enterprises, Northleaf Capital Partners, Point72, Ridgeback Capital, Teralys Capital, PFM Health Sciences, and Surveyor Capital demonstrating strong support for the company's mission. With its headquarters in the United States, Turnstone Biologics is positioned to make meaningful strides in the biotechnology and health and wellness industries. For more information, please visit www.turnstonebio.com.